REGISTER
MedJ at ESMO 2025 with Dr. Paul H. Cottu
MedJ at ESMO 2025 with Dr. Paul H. Cottu stands out in this piece for its practical significance. It pulls together the main findings on ESMO, MD, ER and shows what they may mean for diagnosis, monitoring, prevention, or treatment.

Paul H. Cottu, MD, Institut Curie Paris, France

Ribociclib Combined with Endocrine Neoadjuvant Therapy Delivers a Precision-Intensification Strategy for High-Risk ER+/HER2- Breast Cancer Patients!

0
0
Loading